Abstract:
Despite the improvement in chelating therapy, endocrinologic complications are well documented in patients with hemoglobinopathies requiring frequent and recurrent blood transfusion. The most common findings are delayed puberty and growth failure. Less commonly seen are bone loss, hypothyroidism, and hyperglycemia. In this review, we will explore these complications and discuss management strategies. © 2009 Lippincott Williams and Wilkins, Inc.